the regulatory status of compounded semaglutide and tirzepatide may change materially after this article's publication date
Initiated in 2019, FLOW is a randomized, double-blind, parallel-group, placebo-controlled trial designed to demonstrate the superiority of injectable semaglutide 1.0 mg when used as an adjunct to standard care in people with type 2 diabetes and chronic kidney disease
Obesity as well as type 2 diabetes are chronic conditions, so typically once a medication is started, its not stopped unless its replaced with something else
That said, research has not shown Ozempic to directly worsen ulcerative colitis, but individual responses vary, so caution and monitoring are important
This order establishes the leadership structure for plaintiffs in the GLP-1 Vision Loss litigation